Quick Answer
Bicara Therapeutics Inc. reported Operating Income of -$155.60 million for fiscal year 2025.
Bicara Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$155.60M | -88.9% |
| 2024 | -$82.39M | -106.5% |
| 2023 | -$39.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$40.68M | -97.2% | -27.0% |
| June 30, 2025 | -$32.02M | -62.1% | +23.4% |
| March 31, 2025 | -$41.79M | -171.8% | -102.6% |
| September 30, 2024 | -$20.63M | -116.5% | -4.4% |
| June 30, 2024 | -$19.75M | — | -28.5% |
| March 31, 2024 | -$15.37M | — | -61.3% |
| September 30, 2023 | -$9.53M | — | — |
- Bicara Therapeutics Inc. showed a decrease of -88.9% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Bicara Therapeutics Inc.’s operating income has declined by 290.1% (from -$39.89 million to -$155.60 million).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: